FDA Approves ZERBAXA — Merck Sharp & Dohme LLC

# FDA Approves Merck's ZERBAXA (Ceftolozane and Tazobactam) for Serious Bacterial Infections The FDA has approved Merck Sharp & Dohme LLC's ZERBAXA (ceftolozane and tazobactam), an intravenous antibiotic combination designed to address multidrug-resistant gram-negative bacterial infections, positioning the company to capture market share in the growing segment of hospital-acquired infections. The approval expands Merck's infectious disease portfolio and addresses an unmet clinical need for healthcare providers treating